First Tracks Biotherapeutics (TRAX) Stock

NASDAQ: TRAXHealthcare company in the biotechnology industry, based in San Diego, CA.

First Tracks Biotherapeutics stock price chart

TRAX interactive chart →

TRAX stock quote & key statistics

First Tracks Biotherapeutics earnings per share

Income →
Earnings per share

First Tracks Biotherapeutics revenue & net income

Income →
RevenueNet income

First Tracks Biotherapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2024$0-$163.7M—
FY2023$0-$106.2M—

Fiscal year ending December 31. Source: company filings via EODHD.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs).

First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

First Tracks Biotherapeutics stock FAQ

What is the First Tracks Biotherapeutics stock ticker symbol?

First Tracks Biotherapeutics trades on the NASDAQ under the ticker symbol TRAX.

What sector and industry is First Tracks Biotherapeutics in?

First Tracks Biotherapeutics is classified in the Healthcare sector, Biotechnology industry.

How many employees does First Tracks Biotherapeutics have?

First Tracks Biotherapeutics has about 104 full-time employees.

What were First Tracks Biotherapeutics's revenue and earnings last fiscal year?

First Tracks Biotherapeutics reported revenue of $0 and net income of -$163.7M in fiscal 2024.

Is First Tracks Biotherapeutics in the Russell 2000?

Yes. First Tracks Biotherapeutics (TRAX) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did First Tracks Biotherapeutics go public?

First Tracks Biotherapeutics stock began trading on April 20, 2026.

Russell 2000 Biotechnology stocks

All Russell 2000 →